¹⁸F-FDG PET/CT for Oncological Patients: Procedural Guideline by the Korean Society of Nuclear Medicine Version 2.0

The Korean Society of Nuclear Medicine (KSNM) was founded in 1961 to promote the clinical and technical advancement of nuclear medicine in Republic of Korea. It comprises approximately 600 members, mainly nuclear medicine physicians and related scientists. The KSNM periodically updates guidelines to advance nuclear medicine and help medical professionals provide better patient care. These guidelines are flexible and not obligatory. The KSNM states that these guidelines should not be used in legal actions challenging the medical decisions of healthcare professionals. Final medical decisions should be made by nuclear medicine physicians based on individual patient conditions, available resources, the latest medical knowledge, and technological advances. Deviations from these guidelines does not necessarily indicate substandard care, but rather reflects the application of reasonable clinical judgment. Detailed quality control is to follow the KSNM’s quality control guidelines. Due to the diversity of patients and complexity of medical cases, adherence to guidelines does not always guarantee accurate diagnoses or successful outcomes. This guideline aims to revise the 2013 ‘¹⁸F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Oncological Patients: Procedural Guideline by the KSNM’, ensuring medical professionals take appropriate actions based on current medical knowledge, available resources, and patient needs, ultimately achieving effective and safe imaging. Clinical Trial Number: Not applicable.